银丹心脑通联合石杉碱甲片治疗老年血管性痴呆的临床研究

Clinical research of yindanxinnaotong combined with huperzine A tablets for the treatment in the elderly patients with vascular dementia

目的探讨银丹心脑通联合石杉碱甲片治疗老年血管性痴呆的疗效及安全性。方法选择2015年5月至2017年5月我院收治的95例老年血管性痴呆病人,随机分为对照组(47例)与治疗组(48例)。对照组给予石杉碱甲片治疗,治疗组给予银丹心脑通联合石杉碱甲片治疗,2组均连续治疗6个月。评价并比较2组临床疗效、治疗前后的简易精神状态评价量表(MMSE)评分和痴呆简易筛查量表(BSSD)评分。检测并比较2组治疗前后全血黏度(WBV)、红细胞压积(HCT)及纤维蛋白原(FIB)水平。同时观察2组治疗过程中不良反应的发生情况。结果治疗组和对照组的总有效率分别为97. 92%和85. 11%,2组比较差异有统计学意义(χ~2=5. 053,P=0. 025)。2组治疗后MMSE评分、BSSD评分与治疗前相比均升高,且治疗组升高更明显(P<0. 05)。2组治疗后WBV、HCT及FIB均明显低于治疗前,且治疗组降低更明显(P<0. 05)。治疗组和对照组的不良反应发生率分别为8. 33%和12. 77%,2组比较差异无统计学意义(χ~2=0. 495,P> 0. 05)。结论银丹心脑通联合石杉碱甲片治疗老年血管性痴呆的临床疗效显著,有助于改善老年病人的认知功能及血液流变学指标。

Objective To investigate the clinical efficacy and safty of yindanxinnaotong combined with huperzine A tablets for the treatment in the elderly patients with vascular dementia.Methods Ninty-five cases of elderly patients with vascular dementia in our hospital from May 2015 to May 2017 were divided into the control group ( n = 47) and the research group ( n = 48) randomly. The control group was treated with huperzine A tablets, and the research group was treated with yindanxinnaotong combined with huperzine A tablets. The two groups were all treated for 6 months consecutively. The clinical efficacy and the scores of Mini-Mental State Examination (MMSE) and Brief Screening Scale for Dementia(BSSD) were evaluated and compared in the two groups. The levels of whole blood viscosity(WBV), hematocrit(HCT) and fibrinogen(FIB) in the two groups before and after treatment were detected and compared. The incidence of adverse reaction in the two groups during the treatment were observed.Results The total effective rate of the research group and the control group was 97.92% and 85.11% respectively, and the difference between the two groups was statistically significant (χ^2=5.053, P = 0.025). After treatment, the scores of MMSE and BSSD in the two groups were significantly increased than those before treatment,especially in the research group( P < 0.05).The levels of WBV, HCT,FIB in the two groups were significantly decreased than those before treatment ( P < 0.05), especially in the research group( P < 0.05). During the treatment, the incidence rate of adverse reactions in the research group and the control group was 8.33% and 12.77% repectively, and there was no significant difference between the two groups (χ^2=0.495, P > 0.05).Conclusions Yindanxinnaotong combined with huperzine A tablets is effective in treating vascular dementia in the elderly patients, which can significantly improve the patient s cognitive function and blood rheology indexes.